313 related articles for article (PubMed ID: 26747391)
21. Polypill Variants (Quarter Pill Trials).
Teo K; Yusuf S
Am J Hypertens; 2018 Jun; 31(7):758-761. PubMed ID: 29554202
[TBL] [Abstract][Full Text] [Related]
22. Process evaluation of the impact and acceptability of a polypill for prevention of cardiovascular disease.
Wood F; Salam A; Singh K; Day S; Jan S; Prabhakaran D; Rodgers A; Patel A; Thom S; Ward H
BMJ Open; 2015 Sep; 5(9):e008018. PubMed ID: 26423850
[TBL] [Abstract][Full Text] [Related]
23. Clinical Impact of the Polypill for Cardiovascular Prevention in Latin America: A Consensus Statement of the Inter-American Society of Cardiology.
Sosa-Liprandi Á; Sosa Liprandi MI; Alexánderson E; Avezum Á; Lanas F; López-Jaramillo JP; Martínez F; Ponte-Negretti N CI; Wyss F; González Juanatey JR; Perel P
Glob Heart; 2019 Mar; 14(1):3-16.e1. PubMed ID: 30502220
[TBL] [Abstract][Full Text] [Related]
24. The polypill approach - An innovative strategy to improve cardiovascular health in Europe.
Fuster V; Gambús F; Patriciello A; Hamrin M; Grobbee DE
BMC Pharmacol Toxicol; 2017 Feb; 18(1):10. PubMed ID: 28166827
[TBL] [Abstract][Full Text] [Related]
25. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
26. Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?
Franczyk B; Gluba-Brzózka A; Jurkiewicz Ł; Penson P; Banach M; Rysz J
Expert Opin Pharmacother; 2018 Dec; 19(17):1857-1865. PubMed ID: 30295098
[TBL] [Abstract][Full Text] [Related]
27. Role of the polypill for secondary prevention in ischaemic heart disease.
Castellano JM; Fuster V; Jennings C; Prescott E; Bueno H
Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):44-51. PubMed ID: 28618914
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of use of a polypill versus usual care or best practice for primary prevention in people at high risk of cardiovascular disease.
Jowett S; Barton P; Roalfe A; Fletcher K; Hobbs FDR; McManus RJ; Mant J
PLoS One; 2017; 12(9):e0182625. PubMed ID: 28873416
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries.
Webster R; Patel A; Selak V; Billot L; Bots ML; Brown A; Bullen C; Cass A; Crengle S; Raina Elley C; Grobbee DE; Neal B; Peiris D; Poulter N; Prabhakaran D; Rafter N; Stanton A; Stepien S; Thom S; Usherwood T; Wadham A; Rodgers A;
Int J Cardiol; 2016 Feb; 205():147-156. PubMed ID: 26736090
[TBL] [Abstract][Full Text] [Related]
30. Adherence to therapies for secondary prevention of cardiovascular disease: a focus on aspirin.
Packard KA; Hilleman DE
Cardiovasc Ther; 2016 Dec; 34(6):415-422. PubMed ID: 27473898
[TBL] [Abstract][Full Text] [Related]
31. [The polypill in cardiovascular prevention: successful through simplification? : New study results on the benefit of the polypill strategy in primary and secondary prevention].
Despang P; Schikora M; Doehner W
Inn Med (Heidelb); 2023 Jun; 64(6):598-604. PubMed ID: 37227456
[TBL] [Abstract][Full Text] [Related]
32. The feasibility of polypill for cardiovascular disease prevention in Asian Population.
Sukonthasarn A; Chia YC; Wang JG; Nailes J; Buranakitjaroen P; Van Minh H; Verma N; Hoshide S; Shin J; Turana Y; Tay JC; Teo BW; Siddique S; Sison J; Zhang YQ; Wang TD; Chen CH; Kario K
J Clin Hypertens (Greenwich); 2021 Mar; 23(3):545-555. PubMed ID: 33086429
[TBL] [Abstract][Full Text] [Related]
33. Initiation and maintenance of cardiovascular medications following cardiovascular risk assessment in a large primary care cohort: PREDICT CVD-16.
Mehta S; Wells S; Grey C; Riddell T; Kerr A; Marshall R; Ameratunga S; Harrison J; Kenealy T; Bramley D; Chan WC; Thornley S; Sundborn G; Jackson R
Eur J Prev Cardiol; 2014 Feb; 21(2):192-202. PubMed ID: 23033546
[TBL] [Abstract][Full Text] [Related]
34. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
Sanz G; Fuster V
Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
[TBL] [Abstract][Full Text] [Related]
35. IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care.
Selak V; Elley CR; Crengle S; Harwood M; Doughty R; Arroll B; Bryant L; Rafter N; Hoorn SV; Wadham A; Wells S; Milne R; Jackson R; Bramley D; Rodgers A
Contemp Clin Trials; 2011 Nov; 32(6):909-15. PubMed ID: 21777702
[TBL] [Abstract][Full Text] [Related]
36. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients.
Naderi SH; Bestwick JP; Wald DS
Am J Med; 2012 Sep; 125(9):882-7.e1. PubMed ID: 22748400
[TBL] [Abstract][Full Text] [Related]
37. Polypill treatments for cardiovascular diseases.
Webster R; Rodgers A
Expert Opin Drug Deliv; 2016; 13(1):1-6. PubMed ID: 26558898
[TBL] [Abstract][Full Text] [Related]
38. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry.
Urbinati S; Olivari Z; Gonzini L; Savonitto S; Farina R; Del Pinto M; Valbusa A; Fantini G; Mazzoni A; Maggioni AP;
Eur J Prev Cardiol; 2015 Dec; 22(12):1548-56. PubMed ID: 25452625
[TBL] [Abstract][Full Text] [Related]
39. The polypill: a potential global solution to cardiovascular disease.
Nguyen C; Cheng-Lai A
Cardiol Rev; 2013; 21(1):49-54. PubMed ID: 23018668
[TBL] [Abstract][Full Text] [Related]
40. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
Sanz G; Fuster V
Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):101-10. PubMed ID: 19104519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
